The Latest “Buzz on the Street” Show: Featuring Blueberries Medical (CSE: BBM) (OTCQB: BBRRF) CMO Eduardo Molinari’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Blueberries Medical Appoints Former Abbott Laboratories/AbbVie Pharmaceutical Executive Eduardo Molinari as Chief Marketing Officer.”

Blueberries Medical Corp. (CSE: BBM) (OTCQB: BBRRF) (FRA: 1OA) (the “Company” or “Blueberries“) a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce the appointment of Eduardo Molinari, a former executive of Abbott Laboratories (NYSE: ABT) (“Abbott”) and AbbVie Ltd. (NYSE: ABBV) (“AbbVie”) as Chief Marketing Officer. Mr. Molinari will lead the development and implementation of the Company’s marketing strategies, directing these initiatives in the local and international markets.

Blueberries Medical is seeking to become a large-scale producer of naturally grown premium-quality cannabis with its primary operations well situated in the Bogota savanna in central Colombia. Lead by a specialized team with proprietary expertise in agriculture, genetics, extraction, medicine, pharmacology, and marketing, Blueberries has received all licenses required for the cultivation, production, domestic distribution and international export of cannabidiol (CBD) and tetrahydrocannabinol-based (THC) medical cannabis.

The cannabis industry has recently been finding backers in major global investment banking firms such as Piper Jaffray, RBC Capital Markets, and Cowen. These firms have added credibility to the industry, specifically citing the beneficial uses of cannabis. Piper Jaffray analyst Michael Lavery noted that there are more than 25 countries that have legalized marijuana of some form. Moving forward, Lavery believes that legalization will continue to spread globally, especially within the U.S., even though most countries are adopting cannabis for medical applications, while only a handful are considering recreational use. Despite the limited amount of countries having legalized cannabis, the firms all see potential within the industry. According to data compiled by MarketsandMarkets, the global cannabis market is projected to grow from USD 10.3 Billion in 2018 to USD 39.4 Billion by 2023. Additionally, the market is expected to witness a CAGR of 30.7% during the forecast period. 

Due to the high cost to grow cannabis along with restrictions, many cannabis-based businesses have begun to establish operations elsewhere. The Latin America region has become a popular location for businesses because of its cheap operational costs and fertile land and countries such as Colombia and Argentina have allowed cultivation of cannabis. Now, while countries like Brazil and Argentina are projected to dominate the LATAM region spending on legal cannabis, Colombia is among one of the most popular regions for production facilities. “Colombia’s rich with opportunity,” Eric Logan, Chief Executive Officer of LVE Trust, a leading CBD hemp commodities firm, told Forbes. “The climate to grow is 12 hours of sun, and 12 hours of darkness and grower labor is a mere $500 per month for full-time work,” he reasoned.

For more information, please visit: Blueberries Medical Corp.

For more corporate news on Blueberries Medical Corp., check out the Buzz on the Street

About Buzz on the Street: One of’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.

[popuppress id=”217258″]

  1. Greg Harmon 3 years ago

    wouldn’t international shipment of CBD/THC products disrupt the company’s price points? the cost for shipping can add up.

    • Elsie Amper 3 years ago

      Regardless of whether or not you are traveling to a country where medical cannabis is legal, it is illegal to travel outside of Canada with cannabis products. This is due to a ban on cross-border transport.

Leave a Comment